Patents Represented by Attorney, Agent or Law Firm Elizabeth J. Hecht
-
Patent number: 6426363Abstract: Mupirocin or a salt or ester thereof may be used to treat recurrent sinusitis and recurrent otitis, in particular with novel spray or cream formulations adapted for administration to the nasopharynx.Type: GrantFiled: August 7, 2000Date of Patent: July 30, 2002Assignees: SmithKline Beecham P.L.C., SmithKline Beecham CorporatonInventors: Timothy John Henkel, Anthony Guy Hatton, Teresita Regina Geradine Tallon, Hugh Scott, Jane Elizabeth Hilton
-
Patent number: 6423508Abstract: Human EDG-1c polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Human EDG-1c is identified as a selective receptor for sphingosine-1-phosphate (“S-1-P”) and for di-hydro S-1-P. Also diclsosed are methods for discovering agonists and antagonists of the interaction between S-1-P and di-hydro S-1-P and their cellular receptor, human EDG-1c, which may have utility in the treatment of several human diseases and disorders.Type: GrantFiled: March 4, 1999Date of Patent: July 23, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham PLC, SB Laboratories PharmaceutiquesInventors: Derk J. Bergsma, Winnie Chan, Nassirah Khandoudi, Phillipe Robert
-
Patent number: 6413524Abstract: spsA polypeptides and DNA (RNA) encoding such spsA and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such spsA for the treatment of infection, particularly bacterial infections. Antagonists against such spsA and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of spsA nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding spsA and for detecting the polypeptide in a host.Type: GrantFiled: June 1, 2001Date of Patent: July 2, 2002Assignee: SmithKline Beecham CorporationInventors: Michael T. Black, Karen M. O'Dwyer
-
Patent number: 6365389Abstract: The H2LAU20 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing H2LAU20 polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: October 20, 1999Date of Patent: April 2, 2002Assignee: SmithKline Beecham CorporationInventors: Kimberly Anne Brun, Caretha Lee Creasy, Damien John Dunnington
-
Patent number: 6361967Abstract: AXOR10 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR10 polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: February 11, 1999Date of Patent: March 26, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Pankaj Agarwal, Nabil A. Elshourbagy, David Michalovich, Randall Forrest Smith, Lisa Vawter
-
Patent number: 6361773Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.Type: GrantFiled: October 1, 1997Date of Patent: March 26, 2002Assignee: SmithKline Beecham CorporationInventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, Peter R. Young, James E. Strickler
-
Patent number: 6358725Abstract: Mouse mASP1 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize mouse mASP1. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: Alzheimer's disease, cancer, and prohormone processing.Type: GrantFiled: July 25, 2001Date of Patent: March 19, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Gary Christie, Xiaotong Li, David J. Powell, Yuan Zhu
-
Patent number: 6355452Abstract: Human histamine H3 gene variant-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human histamine H3 gene variant-2 polypeptides and polynucleotides in diagnostic assays.Type: GrantFiled: March 13, 2000Date of Patent: March 12, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham, p.l.c.Inventor: Ping Tsui
-
Patent number: 6350446Abstract: HOEFC11 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HOEFC11 polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal failure, inflammatory diseases, myocardial ischemia, cancer, rheumatoid arthritis, cirrhotic liver disease, among others, and diagnostic assays for such conditions.Type: GrantFiled: August 30, 1999Date of Patent: February 26, 2002Assignee: SmithKline Beecham CorporationInventors: Yuan Zhu, Ponnal Nambi, Mark A Pullen
-
Patent number: 6342371Abstract: The IL-1H4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing IL-1H4 polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: April 16, 1999Date of Patent: January 29, 2002Assignee: SmithKline Beecham CorporationInventors: Peter C McDonnell, Peter R Young
-
Patent number: 6309854Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.Type: GrantFiled: September 26, 1997Date of Patent: October 30, 2001Assignees: Smithkline Beecham Corporation, Board of Regents The University of Texas SystemInventors: Derk J. Bergsma, David P. Brooks, Miklos Gellai, Shelagh Wilson, Masashi Yanagisawa
-
Patent number: 6306583Abstract: Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode a unique subtype of the low Km, cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IVB mRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an ˜4-kb mRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional ˜5-kb hPDE IVB-related mRNA species was detected in brain tissue. Expression of hPDE IVB in a genetically-engineered PDE-deficient strain of the yeast Saccharomym cerevisiae resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: 1) low Km (4.3 &mgr;M) for cAMP, 2) high Km (>3 mM) for cGMP, and 3) sensitivity to rolipram (Ki=0.085 &mgr;M), a selective inhibitor of PDE IV.Type: GrantFiled: May 22, 1995Date of Patent: October 23, 2001Assignee: SmithKline Beecham CorporationInventors: George P. Livi, Megan M. McLaughlin, Theodore J. Torphy
-
Patent number: 6297359Abstract: Human PPP1R5 polypeptides and DNA (RNA) encoding such PPP1R5 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such PPP1R5, or compounds which inhibit or stimulate PPP1R5 for dysfunctions or diseases which involve resistance to the action of insulin on glycogen synthesis are also disclosed. Agonist and antagonists of these PPP1R5 proteins and methods of their use are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the PPP1R5 and for detecting altered levels of the polypeptide in a host.Type: GrantFiled: January 10, 2000Date of Patent: October 2, 2001Assignee: SmithKline Beecham Corporation, et al.Inventors: Peter R. Young, Patricia T. W. Cohen, Phillip Cohen
-
Patent number: 6294364Abstract: Fatty Acid Synthase polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilising Fatty Acid Synthase polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: March 3, 1999Date of Patent: September 25, 2001Assignee: SmithKline Beecham CorporationInventors: Derk J Bergsma, Conrad Chapman, Megan E Depiera, Catherine E Ellis, John Lonsdale, Jeffrey L Mooney
-
Patent number: 6291223Abstract: Mouse mASP1 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize mouse mASP1. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: Alzheimer's disease, cancer, and prohormone processing.Type: GrantFiled: November 21, 2000Date of Patent: September 18, 2001Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Gary Christie, Xiaotong Li, David J. Powell, Yuan Zhu
-
Patent number: 6277960Abstract: HNFDY20 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNFDY20 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: February 9, 1999Date of Patent: August 21, 2001Assignee: SmithKline Beecham CorporationInventors: Derk J. Bergsma, Ganesh M. Sathe, Wendy S. Fuetterer, Joyce Y. Mao
-
Patent number: 6277977Abstract: HAPOI67 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HAPOI67 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: October 23, 1997Date of Patent: August 21, 2001Assignee: SmithKline Beecham CorporationInventors: Ganesh Madhusudan Sathe, Joyce Yue Mao
-
Patent number: 6274717Abstract: The MT-MMP5-L polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing MT-MMP5-L polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: April 20, 1999Date of Patent: August 14, 2001Assignee: SmithKline Beecham CorporationInventors: Anthony J. Arleth, Anne Romanic Arnold, Xiaotong Li, Yuan Zhu
-
Patent number: 6261819Abstract: p101 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing p101 polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: November 17, 2000Date of Patent: July 17, 2001Assignee: SmithKline Beecham plcInventors: Colin Houston MacPhee, Lisa Patel
-
Patent number: 6258934Abstract: FabD polypeptides and DNA (RNA) encoding such FabD and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FabD for the treatment of infection, particularly bacterial infections. Antagonists against such FabD and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FabD nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding Fab (Fatty acid biosynthesis) and for detecting the polypeptide in a host.Type: GrantFiled: July 1, 1998Date of Patent: July 10, 2001Assignee: SmithKline Beecham CorporationInventors: Daniel Robert Gentry, David John Payne, Stewart Campbell Pearson, John Timothy Lonsdale